原因仍不清楚。 - Suppr

Suppr

超能文献

The Reason is Still Unclear.

作者信息

Ogura Masatsune

机构信息

Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute.

出版信息

J Atheroscler Thromb. 2022 Jan 1;29(1):3-4. doi: 10.5551/jat.ED164. Epub 2021 Feb 21.

DOI:10.5551/jat.ED164

PMID:33612709

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8737074/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/941c/8737074/59341a894e7b/29_ED164_1.jpg

相似文献

The Reason is Still Unclear.

J Atheroscler Thromb. 2022 Jan 1;29(1):3-4. doi: 10.5551/jat.ED164. Epub 2021 Feb 21.

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.

J Atheroscler Thromb. 2022 Jan 1;29(1):24-37. doi: 10.5551/jat.58396. Epub 2020 Dec 18.

Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.

Cardiovasc Drugs Ther. 2018 Feb;32(1):73-80. doi: 10.1007/s10557-018-6776-z.

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.

Cardiovasc Diabetol. 2019 Nov 16;18(1):158. doi: 10.1186/s12933-019-0965-3.

Changes in carotid intima-media thickening in patients with type 2 diabetes mellitus: Subanalysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation.

J Diabetes Investig. 2017 Mar;8(2):254-255. doi: 10.1111/jdi.12559.

Sitagliptin for Type 2 diabetes: a 2015 update.

Expert Rev Cardiovasc Ther. 2015 Jun;13(6):597-610. doi: 10.1586/14779072.2015.1046840.

Effects of sitagliptin on coronary atherosclerosis evaluated using integrated backscatter intravascular ultrasound in patients with type 2 diabetes: rationale and design of the TRUST study.

Heart Vessels. 2016 May;31(5):649-54. doi: 10.1007/s00380-015-0662-4. Epub 2015 Mar 21.

Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes.

Atherosclerosis. 2020 May;300:10-18. doi: 10.1016/j.atherosclerosis.2020.03.015. Epub 2020 Mar 21.

Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial).

J Atheroscler Thromb. 2018 Jun 1;25(6):512-520. doi: 10.5551/jat.41343. Epub 2017 Dec 2.

Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease after acute myocardial infarction.

Int J Cardiol. 2016 Nov 1;222:1072-1073. doi: 10.1016/j.ijcard.2015.08.148. Epub 2015 Sep 14.

本文引用的文献

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.

J Atheroscler Thromb. 2022 Jan 1;29(1):24-37. doi: 10.5551/jat.58396. Epub 2020 Dec 18.

Sortilin and Its Multiple Roles in Cardiovascular and Metabolic Diseases.

Arterioscler Thromb Vasc Biol. 2018 Jan;38(1):19-25. doi: 10.1161/ATVBAHA.117.310292. Epub 2017 Nov 30.

Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease.

J Atheroscler Thromb. 2016 Jul 1;23(7):848-56. doi: 10.5551/jat.33407. Epub 2016 Jan 21.

The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion.

Cell Metab. 2014 Feb 4;19(2):310-8. doi: 10.1016/j.cmet.2013.12.006.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The Reason is Still Unclear.

作者信息

Ogura Masatsune

机构信息

Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute.

出版信息

J Atheroscler Thromb. 2022 Jan 1;29(1):3-4. doi: 10.5551/jat.ED164. Epub 2021 Feb 21.

DOI:10.5551/jat.ED164

PMID:33612709

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8737074/

Abstract

摘要

相似文献

The Reason is Still Unclear.

J Atheroscler Thromb. 2022 Jan 1;29(1):3-4. doi: 10.5551/jat.ED164. Epub 2021 Feb 21.

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.

J Atheroscler Thromb. 2022 Jan 1;29(1):24-37. doi: 10.5551/jat.58396. Epub 2020 Dec 18.

Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.

Cardiovasc Drugs Ther. 2018 Feb;32(1):73-80. doi: 10.1007/s10557-018-6776-z.

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.

Cardiovasc Diabetol. 2019 Nov 16;18(1):158. doi: 10.1186/s12933-019-0965-3.

Changes in carotid intima-media thickening in patients with type 2 diabetes mellitus: Subanalysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation.

J Diabetes Investig. 2017 Mar;8(2):254-255. doi: 10.1111/jdi.12559.

Sitagliptin for Type 2 diabetes: a 2015 update.

Expert Rev Cardiovasc Ther. 2015 Jun;13(6):597-610. doi: 10.1586/14779072.2015.1046840.

Effects of sitagliptin on coronary atherosclerosis evaluated using integrated backscatter intravascular ultrasound in patients with type 2 diabetes: rationale and design of the TRUST study.

Heart Vessels. 2016 May;31(5):649-54. doi: 10.1007/s00380-015-0662-4. Epub 2015 Mar 21.

Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes.

Atherosclerosis. 2020 May;300:10-18. doi: 10.1016/j.atherosclerosis.2020.03.015. Epub 2020 Mar 21.

Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial).

J Atheroscler Thromb. 2018 Jun 1;25(6):512-520. doi: 10.5551/jat.41343. Epub 2017 Dec 2.

Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease after acute myocardial infarction.

Int J Cardiol. 2016 Nov 1;222:1072-1073. doi: 10.1016/j.ijcard.2015.08.148. Epub 2015 Sep 14.

本文引用的文献

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.

J Atheroscler Thromb. 2022 Jan 1;29(1):24-37. doi: 10.5551/jat.58396. Epub 2020 Dec 18.

Sortilin and Its Multiple Roles in Cardiovascular and Metabolic Diseases.

Arterioscler Thromb Vasc Biol. 2018 Jan;38(1):19-25. doi: 10.1161/ATVBAHA.117.310292. Epub 2017 Nov 30.

Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease.

J Atheroscler Thromb. 2016 Jul 1;23(7):848-56. doi: 10.5551/jat.33407. Epub 2016 Jan 21.

The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion.

Cell Metab. 2014 Feb 4;19(2):310-8. doi: 10.1016/j.cmet.2013.12.006.